(Q50858454)

24 March 2018

title

Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. (English)

1 reference

24 March 2018

author

Monica Marta

2

1 reference

24 March 2018

Gavin Giovannoni

1

object named as

Gavin Giovannoni

1 reference

24 March 2018

Angharad Davis

3

1 reference

24 March 2018

Benjamin Turner

4

1 reference

24 March 2018

Sharmilee Gnanapavan

5

1 reference

24 March 2018

Klaus Schmierer

6

1 reference

24 March 2018

publication date

25 April 2016

1 reference

24 March 2018

published in

Practical Neurology

1 reference

24 March 2018

volume

16

1 reference

24 March 2018

issue

5

1 reference

24 March 2018

page(s)

389-393

1 reference

24 March 2018

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

cites work

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Fingolimod after natalizumab and the risk of short-term relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001355

10.1136/PRACTNEUROL-2015-001355

21 January 2018

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018